ライフサイエンスコーパス: glucagon-like peptide 1

1 mentation of fibroblast growth factor 21 and glucagon-like peptide 1.

2 eased gastric volume capacity and release of glucagon-like peptide 1.

3 d improved glucose tolerance, dependent upon glucagon-like peptide 1.

4 changes in glucose, insulin, peptide YY, and glucagon-like peptide-1.

5 11%, P = 0.002), NEFA (-21%, P = 0.009), and glucagon-like peptide 1 (-31%, P = 0.001) areas under th

6 enome editing to controllably release GLP-1 (glucagon-like peptide 1), a critical incretin that regul

7 together with the beneficial effects of the glucagon-like peptide-1 agonist exendin-4 in transgenic

8 odium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists, and suggest how such d

9 vestigate the neuroprotective effects of the glucagon-like peptide-1 analog exenatide in resuscitated

10 Glucagon-like peptide-1 analogs are approved for type 2

11 The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-l

12 The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard

13 ontrolled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patien

14 trophy mice and further demonstrate that the glucagon-like peptide-1 analogue exendin-4, a well-toler

15 Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have

16 Liraglutide, a glucagon-like peptide-1 analogue, improves glycaemic con

17 f target engagement for clinical trials with glucagon-like peptide-1 analogues in multiple system atr

18 ulation of cells expressing the precursor of glucagon-like peptide 1 and are glutamatergic; able to m

19 with PS-CF and normal control subjects, and glucagon-like peptide 1 and gastric inhibitory polypepti

20 Levels of glucagon-like peptide 1 and gastric inhibitory polypepti

21 Glucagon-like peptide 1 and glucose-dependent insulinotr

22 improves glucose tolerance while stimulating glucagon-like peptide 1 and insulin secretion.

23 ocrine cells (EECs) produce hormones such as glucagon-like peptide 1 and peptide YY that regulate foo

24 Mean changes in serum glucagon-like peptide 1 and peptide YY were 106.6% +/- 2

25 ther dose affected plasma ghrelin, glucagon, glucagon-like peptide 1 and peptide YY, or pyloric and d

26 rolonging the half-life of incretins such as glucagon-like peptide-1 and gastric inhibitory peptide,

27 ates Ca(2+) , cAMP, and insulin responses to glucagon-like peptide-1 and its metabolites following il

28 es of glucose, insulin, C-peptide, glucagon, glucagon-like peptides 1 and 2, gastric inhibitory pepti

29 y reports activation in response to insulin, glucagon-like peptide 1, and agents that raise cAMP leve

30 ve for either prolactin-releasing peptide or glucagon-like peptide 1, and attenuates the activation o

31 onists, including ADP, arginine vasopressin, glucagon-like peptide 1, and forskolin, and, surprisingl

32 ut hormones, fibroblast growth factor 19 and glucagon-like peptide 1, and the BA transport systems, a

33 , insulin, C-peptide, and incretin hormones; glucagon-like peptide-1; and glucose-dependent insulinot

34 Based on the success of glucagon-like peptide 1-based therapies for type 2 diabe

35 Glucagon-like peptide-1-based (GLP-1-based) therapies im

36 of 14.6% +/- 2.6% and elevated postprandial glucagon-like peptide 1 compared with controls (49.2 +/-

37 g, enhanced postprandial cholecystokinin and glucagon-like peptide 1 concentrations, and reduced ghre

38 lunted the body weight-lowering effects of a glucagon-like peptide-1-estrogen (GLP-1-estrogen) conjug

39 The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) tr

40 w focuses on two peptide drugs - insulin and glucagon-like peptide 1 (GLP-1) - for treatment of type

41 fy 37 T2D patients who were actively using a Glucagon-like peptide 1 (GLP-1) agonist in addition to a

42 Glucagon-like peptide 1 (GLP-1) agonists have shown card

43 The glucagon-like peptide 1 (GLP-1) analog, liraglutide, is

44 Exendin-4 is a long acting glucagon-like peptide 1 (GLP-1) analogue that is an agon

45 ipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase

46 Glucagon-like peptide 1 (GLP-1) and cholecystokinin (CCK

47 Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor ha

48 Glucagon-like peptide 1 (GLP-1) and glucagon-like peptid

49 In contrast, AR231453 increased plasma glucagon-like peptide 1 (GLP-1) and insulin levels and i

50 sized that enteroendocrine L-cells producing glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) may

51 ssed on enteroendocrine L cells that release glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) whe

52 Glucagon-like peptide 1 (GLP-1) and serotonin play criti

53 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandia

54 nsulin increased by 120% +/- 15% (P = 0.02), glucagon-like peptide 1 (GLP-1) by 60% +/- 20% (P < 0.01

55 ecretion of the prosurvival incretin hormone glucagon-like peptide 1 (GLP-1) by alpha cells and acts

56 Exocytosis of the hormone glucagon-like peptide 1 (GLP-1) by the intestinal L cell

57 Since glucagon-like peptide 1 (GLP-1) exerts neuroprotective e

58 Therapeutic engineering of glucagon-like peptide 1 (GLP-1) has enabled development

59 Glucagon-like peptide 1 (GLP-1) immunoreactivity of plas

60 The role of intestinally secreted glucagon-like peptide 1 (GLP-1) in regulation of insulin

61 Glucagon-like peptide 1 (GLP-1) is a hormone with essent

62 The gut hormone called glucagon-like peptide 1 (GLP-1) is a strong moderator of

63 e-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) is characterized by thei

64 Glucagon-like peptide 1 (GLP-1) is known to suppress glu

65 Glucagon-like peptide 1 (GLP-1) is secreted by intestina

66 The incretin glucagon-like peptide 1 (GLP-1) is secreted by the intes

67 The physiologic properties of glucagon-like peptide 1 (GLP-1) make it a potent candida

68 Glucagon-like peptide 1 (GLP-1) mimetics are effective d

69 Moreover, ANP potentiated the effect of glucagon-like peptide 1 (GLP-1) on glucose-induced insul

70 The glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) is a k

71 armacological activation of the hypothalamic glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) promot

72 Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, and ph

73 Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1

74 Glucagon-like peptide 1 (GLP-1) receptor agonists induce

75 al models of type 2 diabetes have shown that glucagon-like peptide 1 (GLP-1) receptor agonists preven

76 e-18]fluoro-levodopa [(18)F-DOPA] PET-CT and glucagon-like peptide 1 (GLP-1) receptor imaging), and d

77 The glucagon-like peptide 1 (GLP-1) receptor is a class B G

78 Glucagon-like peptide 1 (GLP-1) reduces hyperglucagonemi

79 Glucagon-like peptide 1 (GLP-1) regulates glucose homeos

80 gon released from pancreatic alpha cells and glucagon-like peptide 1 (GLP-1) released from intestinal

81 proposed pathway was not influenced by local glucagon-like peptide 1 (GLP-1) secretion from alpha-cel

82 Glucose is an important stimulus for glucagon-like peptide 1 (GLP-1) secretion, but the mecha

83 in from adipocytes and by those means induce glucagon-like peptide 1 (GLP-1) secretion.

84 Centrally administered glucagon-like peptide 1 (GLP-1) supresses food intake.

85 enhancing the action of the incretin hormone glucagon-like peptide 1 (GLP-1) therapeutically improve

86 This study tested the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardia

87 proof-of-principle, the clinically relevant glucagon-like peptide 1 (GLP-1) was functionalized with

88 Glucagon-like peptide 1 (GLP-1) was substantially increa

89 ms mediating the cardioprotective actions of glucagon-like peptide 1 (GLP-1) were unknown.

90 ty acids (FFAs), insulin, glucose, glucagon, glucagon-like peptide 1 (GLP-1), and gastric inhibitory

91 in plasma cholecystokinin, peptide YY (PYY), glucagon-like peptide 1 (GLP-1), and glucagon-like pepti

92 ) inhibitor that inhibits the degradation of glucagon-like peptide 1 (GLP-1), and has been approved f

93 peptide YY3-36 (PYY3-36), lithium chloride, glucagon-like peptide 1 (GLP-1), and leptin shows the pr

94 kinin, gastric inhibitory polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and peptide tyrosine ty

95 wn at regular intervals for cholecystokinin, glucagon-like peptide 1 (GLP-1), and peptide YY (PYY) an

96 elated to changes in blood peptide YY (PYY), glucagon-like peptide 1 (GLP-1), glucose, or insulin con

97 ing glucose, lipids (fasting only), insulin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and g

98 Fasting and postprandial plasma glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and g

99 RC1), general control nonrepressed 2 (GCN2), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), serot

100 Glucagon-like peptide 1 (GLP-1), secreted from intestina

101 diabetes associated with the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow

102 erhans is enhanced by the intestinal hormone glucagon-like peptide 1 (GLP-1), which is secreted from

103 Glucagon-like Peptide 1 (GLP-1)-expressing neurons in th

104 S) in the circulation and thereby stimulates glucagon-like peptide 1 (GLP-1)-mediated insulin secreti

105 Here, we present evidence for glucagon-like peptide 1 (GLP-1)-mediated paraventricular

106 studies in subjects with diabetes receiving glucagon-like peptide 1 (GLP-1)-targeted therapies have

107 stimulates secretion of the incretin hormone glucagon-like peptide 1 (GLP-1).

108 elease of the incretin and satiating peptide glucagon-like peptide 1 (GLP-1).

109 se of satiety-promoting gut hormones such as glucagon-like peptide 1 (GLP-1).

110 Potentiation of glucagon-like peptide-1 (GLP-1) action through selective

111 (OR 0.68, 95% CI 0.58-0.79; p < 0.001), and glucagon-like peptide-1 (GLP-1) agonists (OR 0.37, 95% C

112 Glucagon-like peptide-1 (GLP-1) analogs are approved for

113 dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, are important n

114 Semaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) analogue for type 2 diab

115 ed the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in clinical dev

116 Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 deve

117 Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to s

118 Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic

119 Glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK

120 ate the anorectic effects of both endogenous glucagon-like peptide-1 (GLP-1) and exogenous GLP-1 rece

121 creting glucagon, insulin, and the incretins glucagon-like peptide-1 (GLP-1) and GIP (glucose-depende

122 Glucagon-like peptide-1 (GLP-1) and glucose-dependent in

123 , Tukey's post hoc, P < 0.05]; and increased glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) com

124 e of enteroendocrine L-cell derived hormones glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in

125 elease of gastrointestinal peptides, such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), fr

126 lation to two clinically important peptides: glucagon-like peptide-1 (GLP-1) and the parathyroid horm

127 circulating glucose, insulin, glucagon, and glucagon-like peptide-1 (GLP-1) concentrations and subje

128 d plasma cholecystokinin (CCK), ghrelin, and glucagon-like peptide-1 (GLP-1) concentrations, appetite

129 We have examined analogues of glucagon-like peptide-1 (GLP-1) containing beta-amino ac

130 red changes in cell health and intracellular glucagon-like peptide-1 (GLP-1) content.

131 Glucagon-like peptide-1 (GLP-1) controls glucose homeost

132 The interaction between serotonin (5-HT) and glucagon-like peptide-1 (GLP-1) could play a role as ups

133 Multiple physiological properties of glucagon-like peptide-1 (GLP-1) ensure that it is a prom

134 In this study, we focused on the function of glucagon-like peptide-1 (GLP-1) in initial responses to

135 Pharmacological evidence suggests a role for glucagon-like peptide-1 (GLP-1) in modulating stress res

136 e acid synthesis and intestinal secretion of glucagon-like peptide-1 (GLP-1) in wild-type, Fxr(-/-),

137 Glucagon-like peptide-1 (GLP-1) is a hormone that stimul

138 Glucagon-like peptide-1 (GLP-1) is an incretin hormone w

139 Glucagon-like peptide-1 (GLP-1) is an incretin that play

140 ic polypeptide (GIP) is glucagonotropic, and glucagon-like peptide-1 (GLP-1) is glucagonostatic.

141 Glucagon-like peptide-1 (GLP-1) is produced in the small

142 The multiple physiological properties of glucagon-like peptide-1 (GLP-1) make it a promising drug

143 Since hindbrain glucagon-like peptide-1 (GLP-1) neurons and noradrenergi

144 Here we show that nicotine activates glucagon-like peptide-1 (GLP-1) neurons in the nucleus t

145 impaired; this impairment is ameliorated by glucagon-like peptide-1 (GLP-1) or by GLP-1 receptor ago

146 The BAS-BA complex also induces glucagon-like peptide-1 (GLP-1) production by L cells wh

147 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonis

148 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), gluca

149 Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist adminis

150 Exendin-4 is a glucagon-like peptide-1 (GLP-1) receptor agonist and pot

151 We have generated a humanized glucagon-like peptide-1 (GLP-1) receptor agonist antibod

152 maglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist develop

153 d to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglu

154 Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for gly

155 Exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) receptor agonist, has be

156 Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has ne

157 exposed to thiazolidinediones (glitazones), glucagon-like peptide-1 (GLP-1) receptor agonists and di

158 New drugs for the treatment of diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists and in

159 Glucagon-like peptide-1 (GLP-1) receptor agonists and so

160 Although glucagon-like peptide-1 (GLP-1) receptor agonists and so

161 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

162 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

163 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

164 Glucagon-like peptide-1 (GLP-1) receptor agonists differ

165 body of preclinical evidence indicates that glucagon-like peptide-1 (GLP-1) receptor agonists reduce

166 Two glucagon-like peptide-1 (GLP-1) receptor agonists reduce

167 Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce

168 amine-norepinephrine reuptake inhibitor, and glucagon-like peptide-1 (GLP-1) receptor agonists.

169 The glucagon-like peptide-1 (GLP-1) receptor and the glucose

170 rlap between signaling and regulation of the glucagon-like peptide-1 (GLP-1) receptor by the non-pept

171 a non-peptide agonist, TT-OAD2, bound to the glucagon-like peptide-1 (GLP-1) receptor.

172 The glucagon-like peptide-1 (GLP-1) receptors are important

173 Recent evidence indicates that activation of glucagon-like peptide-1 (GLP-1) receptors in the ventral

174 The glucagon and glucagon-like peptide-1 (GLP-1) receptors play important

175 oid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrin

176 021 to be an especially potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro.

177 etate and early-phase insulin, C-peptide and glucagon-like peptide-1 (GLP-1) secretion were increased

178 Glucagon-like peptide-1 (GLP-1) seems to mediate the met

179 Glucagon-like peptide-1 (GLP-1) signaling through the gl

180 Alhough the glucagon-like peptide-1 (GLP-1) system is critical to en

181 an 11-residue analogue of the N-terminus of glucagon-like peptide-1 (GLP-1) to investigate effects o

182 lasma levels of insulin, leptin, amylin, and glucagon-like peptide-1 (GLP-1) were assessed using Lumi

183 CK in enteroendocrine cells (EECs) that were glucagon-like peptide-1 (GLP-1)(+)/Peptide YY (PYY(-)) i

184 for their production of the incretin hormone glucagon-like peptide-1 (GLP-1), also release other neur

185 Glucagon-like peptide-1 (GLP-1), an incretin secreted by

186 , we use the validated diabetes therapeutic, glucagon-like peptide-1 (GLP-1), and the target of clini

187 hormones, such as cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), are released following

188 lucose, plasma insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), glucose-dependent insul

189 bolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insul

190 FAs and 2-OG, on enteroendocrine secretions [glucagon-like peptide-1 (GLP-1), glucose-dependent insul

191 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), is unknown.

192 on of glucose-regulating hormones, including glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and i

193 ll-bowel motility, other MRI parameters, and glucagon-like peptide-1 (GLP-1), polypeptide YY (PYY), a

194 lation of an important pharmaceutical, human glucagon-like peptide-1 (GLP-1).

195 ed receptors (GPCRs) for glucagon (GluR) and glucagon-like peptide-1 (GLP-1R) are normally considered

196 haracterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years

197 Here, we investigated whether amylin- and glucagon-like-peptide-1 (GLP-1)-based combination therap

198 , dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists, and s

199 ite-related hormones (active ghrelin, active glucagon-like peptide 1 [GLP-1], total peptide YY [PYY],

200 tus and obesity, exemplified by the licensed glucagon-like peptide 1 (GLP1) mimetics and dipeptidyl p

201 We describe this method using dulaglutide, a glucagon-like peptide 1 (GLP1)-Fc fusion protein.

202 .coli and purification of HepoK-incorporated glucagon-like peptide-1 (GLP1) is demonstrated.

203 visceral or cognitive threats that increase glucagon-like peptide-1 (GLP1) signaling from the caudal

204 , we investigated the effects of G49, a dual glucagon-like peptide-1/glucagon receptor agonist, on NA

205 Dual-acting glucagon-like peptide-1/glucagon receptor agonists such

206 nsional ultrasound), plasma cholecystokinin, glucagon-like peptide 1, glucose-dependent insulinotropi

207 n of a long-acting analog of the gut-hormone glucagon-like peptide-1 highlights the therapeutic poten

208 ced and density of endocrine cells secreting glucagon-like peptide-1 increased.

209 h plasma concentrations of acylated ghrelin, glucagon-like peptide 1, insulin, glucose, and nonesteri

210 in human beta-cells, using forskolin or the glucagon-like peptide 1 mimetic Exendin-4, inhibits the

211 Strikingly, when P-NT was combined with the glucagon-like peptide 1 mimetic liraglutide, the two pep

212 eceptor activation, whereas responses to the glucagon-like peptide-1 or the glucagon-like peptide-1 r

213 rs in hippocampal neurons to reduce (leptin, glucagon-like peptide-1) or increase (ghrelin) food inta

214 P = .003), and higher postprandial levels of glucagon-like peptide 1 (P < .001).

215 igher early postprandial cholecystokinin and glucagon-like peptide 1 peaks than did the other partici

216 accompanied by higher secretion of insulin, glucagon-like peptide 1, peptide YY, and cholecystokinin

217 l motility, plasma ghrelin, cholecystokinin, glucagon-like peptide 1, peptide YY, insulin, glucagon,

218 ted depletion, which could not be rescued by glucagon-like peptide 1 pretreatment.

219 nt research has indicated a crucial role for glucagon-like peptide-1-producing preproglucagon (PPG) n

220 us of the solitary tract (cNTS) that produce glucagon-like peptide-1; published work in rodents indic

221 udy assessing the occupancy of the dual GCGR/glucagon like peptide-1 receptor agonist SAR425899.

222 These include biguanides, glucagon-like peptide 1 receptor (GLP-1) agonists, dipep

223 icacy and ability to reduce the body weight, glucagon-like peptide 1 receptor (GLP-1R) agonism has em

224 abetic C57BL/6J mice treated with either the glucagon-like peptide 1 receptor (GLP-1R) agonist liragl

225 Glucagon-like peptide 1 receptor (GLP-1R) agonists are i

226 Glucagon-like peptide 1 receptor (GLP-1R) agonists effec

227 This appeared to be mediated in part by glucagon-like peptide 1 receptor (GLP-1R) and not the G

228 Glucagon-like peptide 1 receptor (GLP-1R) imaging with r

229 The insulinotropic actions of glucagon-like peptide 1 receptor (GLP-1R) in beta-cells

230 like peptide-1 (GLP-1) signaling through the glucagon-like peptide 1 receptor (GLP-1R) is a key regul

231 Glucagon-like peptide 1 receptor (GLP-1R) signaling in t

232 und that exendin-4 (Ex-4), an agonist of the glucagon-like peptide 1 receptor (GLP-1R), stimulates hu

233 gh vagal afferents that require an activated glucagon-like peptide 1 receptor (GLP-1r).

234 DT) with exendin-4-IRDye700DX, targeting the glucagon-like peptide 1 receptor (GLP-1R).

235 ering glucose, incretin drugs, which include glucagon-like peptide 1 receptor (GLP1R) agonists and di

236 Glucagon-like peptide 1 receptor (GLP1R) agonists are wi

237 treatment with thiazolidinedione therapy or glucagon-like peptide 1 receptor agonism alone or in com

238 The short-acting glucagon-like peptide 1 receptor agonist exenatide reduc

239 ctivities of NRTN relative to liraglutide, a glucagon-like peptide 1 receptor agonist, in Zucker diab

240 [(68)Ga]DO3A-VS-Cys(40)-Exendin-4, a glucagon-like peptide 1 receptor agonist, was evaluated

241 odium glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists have consisten

242 Glucagon-like peptide-1 receptor (GLP-1R) activation in

243 ffects of LiCl appear to be mediated through glucagon-like peptide-1 receptor (GLP-1R) activation, we

244 Here we hypothesize that manipulating glucagon-like peptide-1 receptor (GLP-1R) activity selec

245 Exendin-4 (Ex4), a glucagon-like peptide-1 receptor (GLP-1R) agonist approv

246 ble incretin mimetic based upon the specific glucagon-like peptide-1 receptor (GLP-1R) agonist liragl

247 As the anorectic effects of glucagon-like peptide-1 receptor (GLP-1R) agonists are p

248 Glucagon-like peptide-1 receptor (GLP-1R) agonists reduc

249 Glucagon-like peptide-1 receptor (GLP-1R) agonists, wide

250 The glucagon-like peptide-1 receptor (GLP-1R) and the glucag

251 Therapeutic intervention to activate the glucagon-like peptide-1 receptor (GLP-1R) enhances gluco

252 We have shown previously that the incretin glucagon-like peptide-1 receptor (GLP-1R) internalizes f

253 Glucagon-like peptide-1 receptor (GLP-1R) is a class B G

254 The glucagon-like peptide-1 receptor (GLP-1R) is a key thera

255 The glucagon-like peptide-1 receptor (GLP-1R) is expressed i

256 first orally bioavailable and CNS penetrant glucagon-like peptide-1 receptor (GLP-1R) noncompetitive

257 tivated positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), a class B GPC

258 The glucagon-like peptide-1 receptor (GLP-1R), a key pharmac

259 f intraduodenal metformin, and both duodenal glucagon-like peptide-1 receptor (Glp-1r)-protein kinase

260 hibits food-motivated behaviors through vCA1 glucagon-like peptide-1 receptor (GLP-1R).

261 o acid sequence of exendin-4 and targets the glucagon-like peptide-1 receptor (GLP-1R).

262 The glucagon-like peptide-1 receptor (GLP1R) is a class B G

263 mpare the efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide wit

264 ponses to the glucagon-like peptide-1 or the glucagon-like peptide-1 receptor agonist exendin-4 were

265 smotic pump to give continuous delivery of a glucagon-like peptide-1 receptor agonist for 6-12 months

266 To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide add

267 Trial evidence shows that the glucagon-like peptide-1 receptor agonist liraglutide sig

268 e available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but

269 we evaluated the efficacy of a short-course glucagon-like peptide-1 receptor agonist therapy-specifi

270 als, including cholecystokinin, exendin-4 (a glucagon-like peptide-1 receptor agonist), amylin, and m

271 Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of

272 ons in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, and sodium-glu

273 Insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ad

274 lucose-lowering medication occurred, and for glucagon-like peptide-1 receptor agonists (GLP-1 RAs; 3.

275 Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are

276 Both glucagon-like peptide-1 receptor agonists and dipeptidyl

277 However, the distinction may be crucial for glucagon-like peptide-1 receptor agonists and other anti

278 es and consensus statements have recommended glucagon-like peptide-1 receptor agonists and sodium-glu

279 Glucagon-like peptide-1 receptor agonists and sodium-glu

280 Indeed, in several of the new statements, glucagon-like peptide-1 receptor agonists are suggested

281 More data regarding effects of glucagon-like peptide-1 receptor agonists in patients wi

282 to dramatic weight loss in combination with glucagon-like peptide-1 receptor agonists in preclinical

283 More recently, the glucagon-like peptide-1 receptor agonists liraglutide an

284 Although glucagon-like peptide-1 receptor agonists may be appropr

285 Glucagon-like peptide-1 receptor agonists may have addit

286 f dipeptidyl peptidase-4 inhibitors and some glucagon-like peptide-1 receptor agonists, at least in t

287 to micelles, and these micelles activate the glucagon-like peptide-1 receptor with a potency comparab

288 in vivo We further demonstrate that an ileal glucagon-like peptide-1 receptor-dependent neuronal netw

289 ucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists, has changed

290 tidyl-peptidase 4-inhibitor sitagliptin, the glucagon-like peptide 1-receptor agonist lixisenatide ba

291 We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascu

292 e effects of once-weekly exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) versus placeb

293 Glucagon-like peptide 1 receptors (GLP-1Rs) have been fo

294 In nonfasted rats, central antagonism of glucagon-like peptide 1 receptors partially mimics the e

295 Given that PVT neurons express glucagon-like peptide-1 receptors (GLP-1R), which are cr

296 l literature suggests that targeting central glucagon-like peptide-1 receptors (GLP-1Rs) may represen

297 us of the stria terminalis (alBST) expresses glucagon-like peptide-1 receptors (GLP1Rs) and receives

298 for small non-peptide molecules to activate glucagon-like peptide-1 receptors.

299 ntragastric infusion test sessions), whereas glucagon-like peptide 1 responses to milkshake intake we

300 onses to acute stress by "silencing" central glucagon-like peptide 1 signaling pathways.

301 Intriguingly, the central glucagon-like peptide-1 system defined in rodents is con